Republicans Target Prescription Drug Cost Reductions to Win Over Voters Ahead of Midterms

On Monday, December 29, 2025, Rep. Anna Paulina Luna, R-Fla., stated that Republicans could gain a political edge in the upcoming election by codifying President Donald Trump’s executive actions on prescription drug pricing.

Speaking Sunday on Fox News’ “The Big Weekend Show,” Luna emphasized healthcare affordability as one of the Republican Party’s strongest issues ahead of midterms. “There’s a ton that we’re still going to do, and I think one of the biggest winning issues will be if a Republican Congress can codify President Trump’s executive order on capping prescription prices, which I am hopeful that they will do,” Luna said.

Earlier this week, President Trump announced that nine major pharmaceutical companies—Amgen, Bristol Myers Squibb, Boehringer Ingelheim, Genentech, Gilead Sciences, GSK, Merck, Novartis, and Sanofi—had agreed to lower prescription drug costs in the U.S. Under the terms of the deal, these companies will now rein in Medicaid drug prices to match what they charge in other developed countries.

As part of the agreement, new medications from these firms will be priced at the “most-favored-nation” rate nationwide for all markets, including commercial insurance plans and government programs like Medicare and Medicaid.

Luna indicated that action on prescription drug pricing could shift momentum heading into midterm elections. “If that happens, the midterms are with us, the winds are in our sail, and we win and we can continue on bringing prosperity to Americans,” she added.

The Republican strategy focuses on appealing to seniors, working families, and voters frustrated by inflation and rising medical costs. Democrats have countered by highlighting their own legislative achievements, including provisions in the Inflation Reduction Act that allow Medicare to negotiate certain drug prices and cap insulin costs for some seniors.